Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Hamps Bio Limited IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹51
Per ShareLot Size
2000 Shares
Minimum Investment
₹1,02,000
Issue Size
₹6.22 Cr
Face Value
₹10
Per ShareIPO Type
Fixed Price - SME
Retail Quota
50.09%
QIB Quota
0%
NII Quota
49.91%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Promoter Holding (Post-Issue)
71.99%
Issue Type
Fixed Price - SME
ISIN
INE0QBD01018
We are engaged in the ethical marketing and distribution of pharmaceutical formulation products ("Pharma") across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products ("FDFP") such as fruits, vegetables, herbs and flowers. We are recognized in the pharmaceutical industry under our own brand name "Hamps" and in freeze-dried and frozen food segment through our own brand "FzyEzy". We sell our products through more than 50 distributor's network as on October 31, 2024 and E-commerce platform, including Amazon.com, Amazon.ca, Amazon.eu, Flipkart, Jio Mart, Etc. We sell our pharma products primarily in 8 States and Union territories and our FDFP products primarily in 6 countries and 22 States and Union territories. As on the date of this Prospectus, we had a range of more than 180 different products sold across both the segments.
Revenue, profit after tax and total assets across the last 2 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public issue of 12,20,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Hamps Bio Limited ("The Company" or "The Issuer Company") for cash at a price Rs. 51.00/- per equity share (including a share premium of Rs. 41.00/- per equity share) ("Issue Price") aggregating to Rs. 6.22 crores "(The Issue"), out of which 62,000 equity shares of face value of Rs. 10/- each for a cash price of Rs. 51.00/- per equity share, aggregating to Rs. 0.32 crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. issue of 11,58,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 51.00/- per equity share aggregating to Rs. 5.90 crores (is hereinafter referred to as the "Net Issue"). The issue and the net issue will constitute 28.01 % and 26.58 % respectively of the post issue paid up equity share capital of the company. The face value of the equity shares is Rs. 10/- each and the issue price is 5.10 times of the face value.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
India plays an important role in the global pharmaceuticals and vaccine industry. It is the largest provider of generic medicines globally. The country has a share of 20% in the global supply volume and contributes to around 60% of the global vaccines. India ranks third in the world in terms of volume and is the fourteenth largest in terms of value. Key segments of the Indian pharmaceutical industry are OTC medicines, Generics, APIs, Vaccines, Biosimilars, and Custom Research Manufacturing (CRM). The FMCG sector in India expanded due to consumer-driven growth and higher product prices, especially for essential goods. FMCG sector provides employment to around 3 million people accounting for approximately 5% of the total factory employment in India. FMCG sales in the country was expected to grow 7-9% by revenues in 2022-23. The key growth drivers for the sector include favourable Government initiatives & policies, a growing rural market and youth population, new branded products, and growth of e-commerce platforms. Resilience needs to be the key factor in the manufacturing process, daily operations, retail and logistic channels, consumer insights and communication that will help FMCG companies to withstand the test of time and create more value for consumers in the long run.
Our Company was originally incorporated under the name "Hamps Bio Private Limited" under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli on January 02, 2007. Subsequently, the status of the Company was changed to public limited and the name of our Company was changed to "Hamps Bio Limited" vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on June 08, 2023. The fresh certificate of incorporation consequent to conversion was issued on July 12, 2023 by the Registrar of Companies, Ahmedabad, Gujarat. The Corporate Identification Number of our Company is U24233GJ2007PLC049692.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY25 to FY26.